^
Association details:
Biomarker:AXL expression
Cancer:Melanoma
Drug:Yervoy (ipilimumab) (CTLA4 inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

Soluble AXL as a marker of disease progression and survival in melanoma

Excerpt:
Additionally, increased sAXL levels were found correlated with shorter two-year survival in stage IV patients treated with ipilimumab. Furthermore, we showed that sAXL levels were related to the percentage of cells expressing AXL in resected melanoma lymph node metastases.
DOI:
10.1371/journal.pone.0227187